{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:16:34Z","timestamp":1792988194565,"version":"4.5.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Romiplostim is a thrombopoietin (TPO) receptor agonist approved for children and adults with immune thrombocytopenia (ITP) for \u22656 months, recommended as second-line treatment. This phase 3b, single-arm, multicenter study investigated long-term efficacy and safety of romiplostim in children \u22651 to &amp;lt;18 years old with \u22656 months\u2019 ITP duration and platelet counts \u226430\u00a0\u00d7 109\/L. Children received weekly subcutaneous romiplostim (1 \u03bcg\/kg titrated to 10 \u03bcg\/kg) to maintain platelets within 50 to 200\u00a0\u00d7 109\/L. A subset underwent bone marrow examinations. The primary end point was percentage of time with platelet response during the first 6 months\u2019 treatment (counts \u226550\u00a0\u00d7 109\/L without rescue medication within the preceding 4 weeks). Overall, 203 patients (median age, 10.0 years) received \u22651 dose of romiplostim, median treatment duration was \u223c3 years, and median average weekly dose was 6.9 \u03bcg\/kg. Ninety-five (46.8%) discontinued (lack of efficacy, n\u00a0= 43 [21.2%]). Platelet responses were achieved a median (interquartile range) of 50.0% (16.7%-83.3%) of the time during the first 6 months, increasing to 78.2% (26.7%-90.4%) during the overall 36-month treatment period. Eleven patients (5.4%) achieved sustained responses (consecutive counts \u226550\u00a0\u00d7 109\/L without ITP medications for \u226524 weeks). Treatment-related adverse events (AEs) occurred in 56 patients (27.6%), with 8 (3.9%) experiencing serious treatment-related AEs; all of these led to discontinuation, including 4 cases of neutralizing antibodies (romiplostim, n\u00a0= 3; TPO, n\u00a0= 1). Bleeding occurred in 141 patients (69.5%), decreasing over time; grade \u22653 bleeding events occurred in 20 (9.9%). At year 2, eight of 63 evaluable patients (12.7%) had grade 2 reticulin. Long-term romiplostim resulted in sustained on-treatment platelet responses with an overall safety profile consistent with previous studies. This trial was registered at www.clinicaltrials.gov as #NCT02279173.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006014","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T19:26:35Z","timestamp":1649791595000},"page":"396-405","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-0647","authenticated-orcid":false,"given":"John","family":"Grainger","sequence":"first","affiliation":[{"name":"1Department of Haematology, Royal Manchester Children\u2019s Hospital, Faculty of Medical & Human Sciences, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bussel","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Division of Hematology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tarantino","sequence":"additional","affiliation":[{"name":"3The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine\u2013Peoria, Peoria, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cooper","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Hammersmith Hospital, Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Beam","sequence":"additional","affiliation":[{"name":"5Cook Children\u2019s Medical Center, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Despotovic","sequence":"additional","affiliation":[{"name":"6Texas Children\u2019s Hematology Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6698","authenticated-orcid":false,"given":"Alexey","family":"Maschan","sequence":"additional","affiliation":[{"name":"7Dmitry Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejia","family":"Wang","sequence":"additional","affiliation":[{"name":"8Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Eisen","sequence":"additional","affiliation":[{"name":"8Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bowers","sequence":"additional","affiliation":[{"name":"8Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"2023021422371032100_","first-page":"37","article-title":"Romiplostim as a treatment for immune thrombocytopenia: a review","volume":"6","author":"Chalmers","year":"2015","journal-title":"J\u00a0Blood Med"},{"issue":"23","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"},{"issue":"22","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/09537104.2019.1635687","article-title":"The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States","volume":"31","author":"Shaw","year":"2020","journal-title":"Platelets"},{"issue":"3","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"Neunert","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"23","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2009-04-215525","article-title":"Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases","volume":"114","author":"Psaila","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.25086","article-title":"A\u00a0comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up","volume":"93","author":"Schifferli","year":"2018","journal-title":"Am J Hematol"},{"key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/asheducation-2006.1.97","article-title":"Immune thrombocytopenic purpura of childhood","author":"Nugent","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2018-02-830844","article-title":"Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial","volume":"132","author":"Heitink-Poll\u00e9","year":"2018","journal-title":"Blood"},{"key":"2023021422371032100_","author":"Nplate\u00ae. (romiplostim)","year":"2021"},{"issue":"1","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A\u00a0randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"issue":"10039","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/pbc.25136","article-title":"Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP)","volume":"62","author":"Bussel","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3324\/haematol.2018.202283","article-title":"Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia","volume":"104","author":"Tarantino","year":"2019","journal-title":"Haematologica"},{"issue":"16","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"2023021422371032100_","unstructured":"Cancer Therapy Evaluation Program . Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Accessed 6 July 2021. Updated August 9http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"issue":"6","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/bjh.16658","article-title":"Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry","volume":"190","author":"Mytych","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ajcp\/56.1.24","article-title":"Quantitation of bone marrow reticulin\u2014a normal range","volume":"56","author":"Bauermeister","year":"1971","journal-title":"Am J Clin Pathol"},{"key":"2023021422371032100_","first-page":"1","author":"Bain","year":"2001","edition":"3rd ed."},{"issue":"5","key":"2023021422371032100_","first-page":"280","article-title":"How to systematically evaluate immunogenicity of therapeutic proteins\u2014regulatory considerations","volume":"25","author":"Jahn","year":"2009","journal-title":"N\u00a0Biotechnol"},{"issue":"3","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jpeds.2014.03.060","article-title":"Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children","volume":"165","author":"Ramaswamy","year":"2014","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2013.098921","article-title":"Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up","volume":"99","author":"Ghanima","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000452992","article-title":"A\u00a02-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia","volume":"137","author":"Brynes","year":"2017","journal-title":"Acta Haematol"},{"issue":"7","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.24011","article-title":"Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study","volume":"90","author":"Brynes","year":"2015","journal-title":"Am J Hematol"},{"issue":"7","key":"2023021422371032100_","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-016-2682-2","article-title":"Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia","volume":"95","author":"Janssens","year":"2016","journal-title":"Ann Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/396\/2033404\/blooda_adv-2021-006014-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/396\/2033404\/blooda_adv-2021-006014-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T02:01:07Z","timestamp":1726970467000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/3\/396\/484880\/A-single-arm-long-term-efficacy-and-safety-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006014","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]}}}